Physician profile
William Stuart
NPI 1750355731
$5,152.03
in general payments reported to CMS, 2019-2025
24 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $128 · 2021: $451 · 2022: $1,403 · 2023: $1,241 · 2024: $1,173 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,581.20 | 2021-2025 | Mavenclad |
| Celgene Corporation | $1,108.79 | 2019-2024 | Zeposia |
| Novartis Pharmaceuticals Corporation | $580.06 | 2019-2024 | |
| Tg Therapeutics, INC. | $349.49 | 2023-2024 | |
| Abbvie INC. | $325.26 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Biogen, INC. | $186.98 | 2022-2024 | Tysabri, Vumerity, Avonex |
| Horizon Therapeutics Plc | $137.76 | 2022-2023 | Uplizna |
| Alexion Pharmaceuticals, INC. | $134.14 | 2019-2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $133.89 | 2021 | |
| Genentech USA, INC. | $110.93 | 2023 | Ocrevus |
| Amneal Pharmaceuticals LLC | $105.35 | 2023-2024 | Rytary, Lyvispah, Ongentys |
| Acadia Pharmaceuticals INC | $71.58 | 2023-2024 | Nuplazid |
| Ucb, INC. | $58.41 | 2021-2023 | Briviact |
| Merz Pharmaceuticals, LLC | $42.10 | 2022-2024 | Xeomin |
| Otsuka America Pharmaceutical, INC. | $33.83 | 2023-2024 | Nuedexta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $33.10 | 2022-2023 | Vyvgart |
| Lilly USA, LLC | $30.91 | 2022-2024 | Amyvid |
| Eisai INC. | $26.67 | 2024 | |
| Lundbeck LLC | $20.05 | 2024 | Vyepti |
| Astrazeneca Pharmaceuticals Lp | $18.91 | 2023 | Flumist Quadrivalent |
| Banner Life Sciences, LLC | $17.52 | 2024 | |
| Neurocrine Biosciences, INC. | $15.29 | 2023 | Ongentys, Ingrezza |
| Impel Pharmaceuticals INC. | $15.15 | 2023 | Trudhesa |
| Teva Pharmaceuticals USA, INC. | $14.66 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.